Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
<p>Multiple myeloma is a fatal haematological malignancy, in which the majority of patients either present with or develop a destructive and debilitating osteolytic bone disease. The bone disease is characterised by an increase in osteoclastogenesis and by osteoblast suppression. Current trea...
Váldodahkki: | Leng, H |
---|---|
Eará dahkkit: | Simon, K |
Materiálatiipa: | Oahppočájánas |
Giella: | English |
Almmustuhtton: |
2019
|
Fáttát: |
Geahča maid
-
Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
Dahkki: Mabilleau, G, et al.
Almmustuhtton: (2009) -
Stimulation of osteoclast formation by inflammatory synovial fluid
Dahkki: Adamopoulos, I, et al.
Almmustuhtton: (2006) -
Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand
Dahkki: Mabilleau, G, et al.
Almmustuhtton: (2008) -
Expression of Receptor Activator of Nuclear – Kappa β Ligand in Patients with Metastatic Bone Disease
Dahkki: Magetsari, Rahadyan, et al.
Almmustuhtton: (2022) -
Maintenance therapy in multiple myeloma
Dahkki: Jean-Luc Harousseau
Almmustuhtton: (2009-08-01)